New drug aims to stop breast cancer recurrence in High-Risk patients
Disease control
Ongoing
This Phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) can prevent breast cancer from returning in patients with HER2-negative breast cancer who still have cancer after initial chemotherapy. About 1,332 participants will receive either the new drug or standard…
Phase: PHASE3 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC